Summary:
The purpose of the PARALLAX Study is to measure the safety and tolerability of an injectable study drug and its effects on calcium levels in the blood and the amount of calcium passed in the urine, in adults with hypoparathyroidism, when given once a day versus twice a day. Participation in this study includes a screening period, two treatment periods – separated by a washout – and a follow-up visit. The maximum total duration of study participation will be approximately 90 days if the maximum screening, washout, and follow-up visit durations are used.
All study-related tests and clinic visits are provided at no charge
All study medications are provided
You will need to stay overnight at the clinical research center for at least three nights during each of the two treatment periods.
Participants may receive compensation for travel
Qualified Participants Must:
• History of hypoparathyroidism ≥ 12 months
•
Requirement for supplemental oral calcium treatment ≥ 1000 mg per day
•
Requirement for active vitamin D therapy at a dose of ≥ 0.25 micrograms per day
•
Qualified participants must meet additional inclusion and exclusion criteria